Apixaban versus warfarin in patients with atrial fibrillation

Cited by (1,013)

Items 301–400 of 1,013

1. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics
   Sophie Testa, Armando Tripodi, Cristina Legnani, Vittorio Pengo, Rosanna Abbate, Claudia Dellanoce, Paolo Carraro, Luisa Salomone, Rita Paniccia, Oriana Paoletti et al. · 2015 · Thrombosis Research
2. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
   François Laliberté, Michel Cloutier, Winnie W. Nelson, Craig Ian Coleman, Dominic Pilon, William H. Olson, C.V. Damaraju, Jeffrey R Schein, Patrick Lefèbvre · 2014 · Current Medical Research and Opinion
3. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
   Antonio Gómez‐Outes, Ana Isabel Terleira‐Fernández, Gonzalo Calvo, Ma Luisa Suárez‐Gea, Emilio Vargas · 2013 · Thrombosis
4. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
   Rikke Sørensen, Gunnar Gislason, Christian Tobias Torp-Pedersen, Jonas Bjerring Olesen, Emil Loldrup Fosbøl, Morten Winther Hvidtfeldt, Deniz Karasoy, Morten Lamberts, Mette Gitz Charlot, Lars Køber et al. · 2013 · BMJ Open
5. New Oral Anticoagulants and the Risk of Intracranial Hemorrhage
   Saurav Chatterjee, Partha Sardar, Giuseppe Biondi‐Zoccai, Dharam J. Kumbhani · 2013 · JAMA Neurology
6. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
   Michiel Coppens, John W. Eikelboom, Robert G. Hart, Salim Yusuf, Gregory Y.H. Lip, Paul Dorian, Olga Shestakovska, Stuart J. Connolly · 2012 · European Heart Journal
7. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin
   Matthew William Sherwood, Christopher C. Nessel, Anne S. Hellkamp, Kenneth W. Mahaffey, Jonathan Paul Piccini, Eunyoung Suh, Richard Clinton Becker, Daniel E. Singer, Jonathan L. Halperin, Graeme J. Hankey et al. · 2015 · Journal of the American College of Cardiology
8. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
   Thorsten Steiner, Michael Böhm, Martin Dichgans, HC Diener, Christian Ell, Matthias Endres, Corina Epple, Martin Grond, Ulrich Laufs, Georg Nickenig et al. · 2013 · Clinical Research in Cardiology
9. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
   Jeroen Jaspers Focks, Marc A. Brouwer, DANIEL M. WOJDYLA, Laine Elliott Thomas, Renato D. Lópes, Jeffrey B. Washam, Fernando Tomas Lanas, Denis Xavier, Steen Husted, Lars C. Wallentin et al. · 2016 · BMJ
10. Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
    Jonas Oldgren, Signild Åsberg, Ziad Hijazi, Per Olov Wester, Maria Bertilsson, Bo G Norrving, for the National TIMING Collaborators · 2022 · Circulation
11. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark
    Kasper Gadsbøll, Laila Stærk, Emil Loldrup Fosbøl, Caroline Sindet‐Pedersen, Anna Gundlund, Gregory Y.H. Lip, Gunnar Gislason, Jonas Bjerring Olesen · 2016 · European Heart Journal
12. Asundexian versus Apixaban in Patients with Atrial Fibrillation
    Jonathan Paul Piccini, Manesh R. Patel, Jan Steffel, Keith C. Ferdinand, Isabelle C. Van Gelder, Andrea M. Russo, Chang-Sheng Ma, Shaun G. Goodman, Jonas Oldgren, Christopher J.K. Hammett et al. · 2024 · New England Journal of Medicine
13. Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke
    Jennifer E. Fugate, Alejandro A. Rabinstein · 2015 · The Neurohospitalist
14. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis
    Piérre Siè, Charles Marc Samama, Anne Godiér, Nadia Rosencher, A. Steib, Juan V. Llau, Philippe Van der Linden, Gilles Pernod, Thomas Lecompte, Isabelle Gouin‐Thibault et al. · 2011 · Archives of cardiovascular diseases
15. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
    Victoria Allan, Sreeram V Ramagopalan, Jack Mardekian, Aaron K. Jenkins, Xiaoyan Li, Xianying Pan, Xuemei Luo · 2020 · Journal of Comparative Effectiveness Research
16. Adherence to oral anticoagulant therapy in patients with atrial fibrillation
    Valeria Raparelli, Marco Proietti, Roberto Cangemi, Gregory Y.H. Lip, Deirdre A. Lane, Stefania Basili · 2016 · Thrombosis and Haemostasis
17. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial
    Linda P.T. Joosten, Sander van Doorn, Peter M. van de Ven, B T G Kohlen, Melchior C. Nierman, Huiberdina L. Koek, Martin E W Hemels, Menno Volkert Huisman, Marieke J.H.A. Kruip, Laura M. Faber et al. · 2023 · Circulation
18. Secondary stroke prevention: challenges and solutions
    José Gutierrez, Charles C. Esenwa · 2015 · Vascular Health and Risk Management
19. Vascular calcification: The price to pay for anticoagulation therapy with vitamin K-antagonists
    Martijn L. L. Chatrou, Kristien Winckers, Tilman M. Hackeng, Chris P.M. Reutelingsperger, Leon J. Schurgers · 2012 · Blood Reviews
20. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis
    Armando Tripodi, Massimo Primignani, Laura Lemma, Veena Chantarangkul, Pier Mannuccio Mannucci · 2013 · Journal of Hepatology
21. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time
    Ziad Hijazi, Stefan Hans Hohnloser, Ulrika Andersson, John Hunter Alexander, Michael Hanna, Mátyás Keltai, Alexander N. Parkhomenko, Jose Luis Lopez-Sendon, Renato D. Lópes, Agneta Siegbahn et al. · 2016 · JAMA Cardiology
22. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation
    Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, Álvaro Alonso · 2018 · Blood Advances
23. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Dialysis
    Toshiki Kuno, Hisato Takagi, Tomo Ando, Takehiro Sugiyama, Satoshi Miyashita, Nelson Valentin, Yuichi J. Shimada, Masaki Kodaira, Yohei Numasawa, Αlexandros Briasoulis et al. · 2020 · Journal of the American College of Cardiology
24. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC
    Anja Katholing, Christopher Wallenhorst, Saul Benedict Freedman, Carlos Martínez · 2015 · Thrombosis and Haemostasis
25. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
    Claes Held, Elaine M. Hylek, John Hunter Alexander, M. Hanna, Renato D. Lópes, DANIEL M. WOJDYLA, Laine Elliott Thomas, Hussein R. Al‐Khalidi, Marco Alings, Denis Xavier et al. · 2014 · European Heart Journal
26. Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease
    Joseph Pierre Aboumsallem, Javid J. Moslehi, Rudolf A. de Boer · 2020 · Journal of the American Heart Association
27. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
    Ming Chang, Zhigang Yu, Andrew Shenker, Jessie J.J. Wang, Janice M. Pursley, Wonkyung Byon, Rebecca A. Boyd, Frank P. LaCreta, Charles E. Frost · 2015 · The Journal of Clinical Pharmacology
28. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence
    Bernard Vrijens, Hein Heidbüchel · 2015 · EP Europace
29. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes
    Candrika D. Khairani, Antoine Bejjani, Gregory Piazza, David Jiménez, Manuel Monréal, Saurav Chatterjee, Vittorio Pengo, Scott C. Woller, Josefina Cortés-Hernández, Jean M. Connors et al. · 2022 · Journal of the American College of Cardiology
30. Non-inferiority study design: lessons to be learned from cardiovascular trials
    Stuart J. Head, Sanjay Kaul, Ad J.J.C. Bogers, A. Pieter Kappetein · 2012 · European Heart Journal
31. Effectiveness and Safety of Non–vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses
    Abdulaali R. Almutairi, Lili Zhou, Walid F. Gellad, Jeannie K. Lee, Marion Kimball Slack, Jennifer R Martin, Wei-Hsuan Lo-Ciganic · 2017 · Clinical Therapeutics
32. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures
    David A. Garcia, John Hunter Alexander, Lars C. Wallentin, DANIEL M. WOJDYLA, Laine Elliott Thomas, Michael Hanna, Sana M. Al‐Khatib, Paul Dorian, Jack Ansell, Patrick Commerford et al. · 2014 · Blood
33. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
    Michael D. Ezekowitz, Charles V. Pollack, Jonathan L. Halperin, Richard D. England, Sandra VanPelt Nguyen, Judith Spahr, Maria Sudworth, Nilo B. Cater, Andrei Breazna, Jonas Oldgren et al. · 2018 · European Heart Journal
34. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal
    Gregory Y.H. Lip, Marco Proietti, Tatjana Potpara, MOUSSA C. MANSOUR, Irina Savelieva, Hung‐Fat Tse, Andreas Goette, A. John Camm, Carina Blomström‐Lundqvist, Dhiraj Gupta et al. · 2023 · EP Europace
35. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
    John W. Stanifer, Sean D. Pokorney, Glenn Matthew Chertow, Stefan Hans Hohnloser, DANIEL M. WOJDYLA, Samira J. Merali, Wonkyung Byon, Ziad Hijazi, Renato D. Lópes, John Hunter Alexander et al. · 2020 · Circulation
36. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial
    Scott C. Woller, Scott M. Stevens, David Kaplan, Tzu‐Fei Wang, David Ware Branch, Danielle Groat, Emily L. Wilson, Brent P. Armbruster, Valerie T. Aston, James F. Lloyd et al. · 2021 · Blood Advances
37. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play
    Lampert, Rachel, Chung, Eugene H., Ackerman, Michael J., Arroyo, Alonso Rafael, Darden, Douglas, Deo, Rajat, Dolan, Joe, Etheridge, Susan P., Gray, Belinda R., Harmon, Kimberly G. et al. · 2024 · Heart Rhythm
38. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review
    Dorothy M. Adcock, Robert C. Gosselin · 2015 · Thrombosis Research
39. Antithrombotic Therapy in Patients With Chronic Kidney Disease
    Davide Capodanno, Dominick Joseph Angiolillo · 2012 · Circulation
40. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling
    Jan Steffel, Robert Patrick Giugliano, Eugene Braunwald M. D, Sabina A. Murphy, Michele F. Mercuri, Youngsook Choi, Philip E. Aylward, Harvey Douglas White, José Luis Zamorano, Elliott Marshall Antman et al. · 2016 · Journal of the American College of Cardiology
41. Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting
    Jerrold H. Levy, David Faraoni, Jenna L. Spring, James Demetrios Douketis, Charles Marc Samama · 2013 · Anesthesiology
42. Acute management of bleeding in patients on novel oral anticoagulants
    Deborah M. Siegal, Mark Andrew Crowther · 2012 · European Heart Journal
43. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
    Chiara Melloni, Allison M. Dunning, Christopher Bull Granger, Laine Elliott Thomas, Michel Georges Khouri, David A. Garcia, Elaine M. Hylek, Michael Hanna, Lars C. Wallentin, Bernard John Gersh et al. · 2017 · The American Journal of Medicine
44. Factors Associated With Thrombotic Complications After the Fontan Procedure
    Brian W. McCrindle, Cedric Manlhiot, Andrew Donald Cochrane, Robin E. Roberts, Marina L. Hughes, Barbara Szechtman, Robert Gideon Weintraub, Maureen E. Andrew, Paul Monagle · 2012 · Journal of the American College of Cardiology
45. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation
    Heyder Omran, Rupert Martin Bauersachs, Siegfried Rübenacker, Franz Goss, Christoph Hammerstingl · 2012 · Thrombosis and Haemostasis
46. What is ‘valvular’ atrial fibrillation? A reappraisal
    Raffaele De Caterina, A. John Camm · 2014 · European Heart Journal
47. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013
    Jonas Bjerring Olesen, Rikke Sørensen, Morten Lock Hansen, Morten Lamberts, Peter Ejvin Weeke, Anders Pretzmann Mikkelsen, Lars Køber, Gunnar Gislason, Christian Tobias Torp-Pedersen, Emil Loldrup Fosbøl · 2014 · EP Europace
48. An update of consensus guidelines for warfarin reversal
    Huyen Anh Tran, Sanjeev Daya Chunilal, Paul L. Harper, Huy Tran, Erica M. Wood, Alexander S. Gallus · 2013 · The Medical Journal of Australia
49. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies
    Apostolos Tzikas, David R. Holmes, Sameer A. Gafoor, Carlos Eduardo Ruiz, Carina Blomström‐Lundqvist, Hans‐Christoph Diener, Riccardo Cappato, Saibal Kar, Randal J. Lee, Robert A. Byrne et al. · 2016 · EuroIntervention
50. Social determinants of atrial fibrillation
    Utibe R. Essien, Jelena Kornej, Amber E. Johnson, Lucy Schulson, Emelia J. Benjamin, Jared W. Magnani · 2021 · Nature Reviews Cardiology
51. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study
    Friberg, Leif, Benson, Lina, Lip, Gregory Y.H. · 2015 · European Heart Journal
52. Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
    Shinya Goto, Jun Zhu, Lisheng Liu, Byung‐Hee Oh, DANIEL M. WOJDYLA, Philip E. Aylward, Maria Cecilia Bahit, Bernard John Gersh, Michael Hanna, John David Horowitz et al. · 2014 · American Heart Journal
53. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
    Michael D. Ezekowitz, Rangadham Nagarakanti, Herbert Noack, Martina Brueckmann, Claire Litherland, Mark Jacobs, Andreas Clemens, Paul A. Reilly, Stuart J. Connolly, Salim Yusuf et al. · 2016 · Circulation
54. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
    Tobias Geisler, Sven Poli, Christoph Meisner, Jüergen Schreieck, Christine S. Zuern, Thomas Nägele, Johannes Brachmann, Werner Jung, Georg Gahn, Elisabeth Verena Schmid et al. · 2016 · International Journal of Stroke
55. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition)
    Samer Narouze, Honorio T. Benzon, David Anthony Provenzano, Asokumar Buvanendran, José Antonio De Andrés, Timothy Ray Deer, Richard L Rauck, Marc Alan Huntoon · 2017 · Regional Anesthesia & Pain Medicine
56. Detection of Previously Undiagnosed Atrial Fibrillation in Patients With Stroke Risk Factors and Usefulness of Continuous Monitoring in Primary Stroke Prevention
    Paul Ziegler, Taya V. Glotzer, Emile G. Daoud, Daniel E. Singer, Michael D. Ezekowitz, ROBERT H. HOYT, Jodi L. Koehler, James A. Coles, D. George Wyse · 2012 · The American Journal of Cardiology
57. Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies
    Guangchen Li, Yifu Cheng, Chi Han, Chun Song, Niu Huang, Yunfei Du · 2022 · RSC Medicinal Chemistry
58. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation
    Victoria Jacobs, Heidi Thomas May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Charles D. Mallender, Jeffrey S. Osborn, Scott M. Stevens, J. Peter Weiss et al. · 2016 · The American Journal of Cardiology
59. Stroke and Thromboembolism in Atrial Fibrillation
    Ron Pisters, Deirdre A. Lane, Francisco R. Marín, A. John Camm, Gregory Y.H. Lip · 2012 · Circulation Journal
60. Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation
    John J.V. McMurray, Justin Adrian Ezekowitz, Basil S. Lewis, Bernard John Gersh, Sean van Diepen, John V. Amerena, Jozef Bartúnek, Patrick Commerford, Byung‐Hee Oh, Veli‐Pekka Harjola et al. · 2013 · Circulation Heart Failure
61. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation
    Judith S. Hecker, Sandra Marten, Loretta Keller, Sindy Helmert, Franziska Michalski, Sebastian Werth, Kurtuluş Şahin, Luise Tittl, Jan Beyer‐Westendorf · 2016 · Thrombosis and Haemostasis
62. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice
    Xiaoyan Li, Steve Deitelzweig, Allison V. Keshishian, Melissa Hamilton, Ruslan V. Horblyuk, Kiran B. Gupta, Xuemei Luo, Jack Mardekian, Keith E. Friend, Anagha Nadkarni et al. · 2017 · Thrombosis and Haemostasis
63. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
    Shadi R. Yaghi, Liqi Shu, Ekaterina Bakradze, Setareh Salehi Omran, James A. Giles, Jordan Yardain Amar, Nils Henninger, Marwa Elnazeir, Ava Leigh Liberman, Khadean Moncrieffe et al. · 2022 · Stroke
64. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor X a inhibitor
    Charles E. Frost, Wonkyung Byon, Yan Jun Song, Jessie J.J. Wang, Alan E. Schuster, Rebecca A. Boyd, Donglu Zhang, Zhigang Yu, Clapton S. Dias, Andrew Shenker et al. · 2014 · British Journal of Clinical Pharmacology
65. Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants
    Sophie Testa, Oriana Paoletti, Cristina Legnani, Claudia Dellanoce, Emilia Antonucci, Benilde Cosmi, Vittorio Pengo, D. Poli, Rossella Morandini, Roberto Testa et al. · 2018 · Journal of Thrombosis and Haemostasis
66. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study
    Di Biase, Luigi, Lakkireddy, Dhanujaya, Trivedi, Chintan, Deneke, Thomas, Martinek, Martin, Mohanty, Sanghamitra, Mohanty, Prasant, Prakash, Sameer, Bai, Rong, Reddy, Madhu et al. · 2015 · Heart Rhythm
67. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II
    Essien, Utibe R., Holmes, DaJuanicia N., Jackson, Larry R., Fonarow, Gregg C., Mahaffey, Kenneth W., Reiffel, James A., Steinberg, Benjamin A., Allen, Larry A., Chan, Paul S., Freeman, James V. et al. · 2018 · JAMA Cardiology
68. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
    Kirchhof, Paulus, Breithardt, Günter, Camm, A. John, Crijns, Harry J., Kuck, Karl-Heinz, Vardas, Panos, Wegscheider, Karl · 2013 · American Heart Journal
69. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
    John Hunter Alexander, Renato D. Lópes, Laine Elliott Thomas, Marco Alings, Dan Atar, Philip E. Aylward, Shinya Goto, M. Hanna, Kurt Huber, Steen Husted et al. · 2013 · European Heart Journal
70. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration
    Ryan T. Borne, Colin I. O’Donnell, Mintu P. Turakhia, Paul D. Varosy, Cynthia Anne Jackevicius, Lucas Marzec, Frederick A. Masoudi, Paul L. Hess, Thomas M. Maddox, P. Michael Ho · 2017 · BMC Cardiovascular Disorders
71. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording
    Aronsson, Mattias, Svennberg, Emma, Rosenqvist, Mårten, Engdahl, Johan, Al-Khalili, Faris, Friberg, Leif, Frykman-Kull, Viveka, Levin, Lars-Åke · 2015 · Europace
72. Percutaneous Left Atrial Appendage Closure
    Jacqueline Saw, Mathieu Lempereur · 2014 · JACC: Cardiovascular Interventions
73. Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
    Xiaoli Wang, Sabiha A. Mondal, Jessie J.J. Wang, Giridhar Tirucherai, Donglu Zhang, Rebecca A. Boyd, Charles E. Frost · 2013 · American Journal of Cardiovascular Drugs
74. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
    Jack Ansell, Simon H Mantha · 2012 · Thrombosis and Haemostasis
75. Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation
    Rory Hachamovitch · 2012 · Archives of Internal Medicine
76. Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes
    Laurel A. Grisanti · 2018 · Frontiers in Physiology
77. Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
    Ji‐Guang Wang · 2025 · 老年心脏病学杂志：英文版
78. Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation
    Benjamin Adam Steinberg, Sunghee Kim, Jonathan Paul Piccini, Gregg C. Fonarow, Renato D. Lópes, Laine Elliott Thomas, Michael D. Ezekowitz, Jack Ansell, Peter Russell Kowey, Daniel E. Singer et al. · 2013 · Circulation
79. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation
    Björck, Fredrik, Renlund, Henrik, Lip, Gregory Y. H., Wester, Per, Svensson, Peter J., Själander, Anders · 2016 · JAMA Cardiology
80. Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Ntaios, George, Papavasileiou, Vasileios, Diener, Hans-Christoph, Makaritsis, Konstantinos, Michel, Patrik · 2012 · Stroke
81. High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin
    Ziad Hijazi, Lars C. Wallentin, Agneta Siegbahn, Ulrika Andersson, John Hunter Alexander, Dan Atar, Bernard John Gersh, Michael Hanna, Veli‐Pekka Harjola, John David Horowitz et al. · 2013 · Journal of the American College of Cardiology
82. Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement
    Julia Seeger, Birgid Gonska, Christoph Rodewald, Wolfgang Rottbauer, Jochen Wöhrle · 2017 · JACC: Cardiovascular Interventions
83. Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
    Kuo‐Li Pan, Daniel E. Singer, Bruce Ovbiagele, Yi‐Ling Wu, Mohamed Ahmed, Meng Lee · 2017 · Journal of the American Heart Association
84. 2018 Korean Guideline of Atrial Fibrillation Management
    Boyoung Joung, Jung‐Myung Lee, Ki Hong Lee, Tae‐Hoon Kim, Eue‐Keun Choi, Woo‐Hyun Lim, Ki‐Woon Kang, Jae‐Sun Uhm, Hong Euy Lim, Junbeom Park et al. · 2018 · Korean Circulation Journal
85. Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
    Sally G. Tamayo, W. Frank Peacock, Manesh R. Patel, Nicholas Sicignano, Kathleen Pillsbury Hopf, Larry E. Fields, Troy C. Sarich, Shujian Wu, Daniel Yannicelli, Žhong Yuan · 2015 · Clinical Cardiology
86. National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
    Jeffrey S. Dlott, Roberta George, Xiaohua Huang, Mouneer A. Odeh, Harvey W. Kaufman, Jack Ansell, Elaine M. Hylek · 2014 · Circulation
87. Risk factors for intracerebral hemorrhage differ according to hemorrhage location
    Sharyl R. Martini, Matthew L. Flaherty, W. Mark Brown, Mary A. Haverbusch, Mary E. Comeau, Laura R. Sauerbeck, Brett M. Kissela M. D, Ranjan Deka, Dawn Kleindorfer, Charles J. Moomaw et al. · 2012 · Neurology
88. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
    Keith A.A. Fox, Joseph E. Lucas, Karen S. Pieper, Jean‐Pierre Bassand, A. John Camm, David Andrew Fitzmaurice, Samuel Zachary Goldhaber, Shinya Goto, Sylvia K. Haas, Werner Hacke et al. · 2017 · BMJ Open
89. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
    Danielle Clarkesmith, Helen M. Pattison, Phyo Khaing, Deirdre A. Lane · 2017 · Cochrane Database of Systematic Reviews
90. Stroke prevention in atrial fibrillation—An Asian stroke perspective
    Hung‐Fat Tse, Yong Jun Wang, Moheeb Ahmed Ai-Abdullah, Annette Borromeo, Chern‐En Chiang, Rungroj Krittayaphong, Balbir Bagicha Singh, Amit M. Vora, Chunxue Wang, Mohammad Zubaid et al. · 2013 · Heart Rhythm
91. Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
    Doug Coyle, Kathryn Coyle, Chris G Cameron, Karen S. Lee, Shannon Kelly, Sabine Steiner, George A. Wells · 2013 · Value in Health
92. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri‐procedural/bleeding management
    H. Tran, Joanne Emily Joseph, L. Young, Simon J. McRae, Jennifer L. Curnow, Harshal H. Nandurkar, Peter Wood, Claire McLintock · 2014 · Internal Medicine Journal
93. Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure
    Jorge A. Wong, David Conen, Isabelle C. Van Gelder, William F. McIntyre, Harry J.G.M. Crijns, Jia Wang, Michael Robert Gold, Stefan Hans Hohnloser, Chu‐Pak Lau, Alessandro Capucci et al. · 2018 · Journal of the American College of Cardiology
94. Reversal of anticoagulants: an overview of current developments
    Thomas Thiele, Kathleen Selleng, Andreas Greinacher · 2015 · Thrombosis and Haemostasis
95. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
    Yi‐Hsin Chan, Lai‐Chu See, Hui‐Tzu Tu, Yung‐Hsin Yeh, Shang‐Hung Chang, Lung‐Sheng Wu, Hsin‐Fu Lee, Chun‐Li Wang, Chang‐Fu Kuo, Chi-Tai Kuo · 2018 · Journal of the American Heart Association
96. Antithrombotic drugs and risk of hemorrhagic stroke in the general population
    L. García-Rodríguez, D. Gaist, J. Morton, C. Cookson, A. Gonzáléz-Pérez · 2013 · Neurology
97. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients
    Morten Lamberts, Laila Stærk, Jonas Bjerring Olesen, Emil Loldrup Fosbøl, Morten Lock Hansen, Louise Harboe, Cinira Lefèvre, David Evans, Gunnar Gislason · 2017 · Journal of the American Heart Association
98. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis
    Bianca Rocca, Keith A.A. Fox, Ramzi Ajjan, Felicita Andreotti, Colin Baigent, Jean‐Philippe Collet, Erik Lerkevang Grove, Sigrun Halvorsen, Kurt Huber, João Morais et al. · 2018 · European Heart Journal
99. Atrial Fibrillation
    Gregory F. Michaud, William G. Stevenson · 2021 · New England Journal of Medicine
100. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
     Menno Volkert Huisman, Gregory Y.H. Lip, Hans‐Christoph Diener, Sérgio Dubner, Jonathan L. Halperin, Shang‐Hung Chang, Kenneth Jay Rothman, Christine Teutsch, Kristina Zint, Diana Ackermann et al. · 2013 · American Heart Journal